GBG Forschungs GmbH’s Post

NEW from #ASCO24 | PALOMA-3: #subcutaneous vs #intravenous #amivantamab + #lazertinib in refractory EGFR-mutated #NSCLC 🎥 🫁 Natasha Leighl, MD, FASCO, Princess Margaret Cancer Centre, discusses the findings of the Phase III PALOMA-3 (NCT05388669) trial, which evaluated subcutaneous (SC) versus intravenous (IV) administration of amivantamab plus lazertinib in patients with #EGFR-mutated advanced #nonsmallcell #lungcancer (NSCLC) 🌟 The study met its co-primary endpoints, demonstrating noninferior #pharmacokinetics (PK) and objective response rate (ORR) for SC administration 🌟 SC #amivantamab showed a median progression-free survival (PFS) of 6.1 months versus 4.3 months for IV, and an overall survival (OS) advantage with a hazard ratio of 0.62. 🌟 The SC form also resulted in significantly lower infusion-related reactions (IRRs) and venous thromboembolism (VTE) rates These results suggest a favorable profile for SC administration in terms of efficacy and safety 💡 Learn more 👉 https://lnkd.in/eTsDjBaA #VJOncology #Oncologynews #LCsm

Did you know that the recent findings of DESTINY-Breast06 phase III study, supported by AstraZeneca in collaboration with Daiichi Sankyo Brasil , demonstrated that trastuzumab deruxtecan significantly improved progression-free survival (PFS) compared to chemotherapy in patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after prior endocrine therapy? The trial highlighted consistent benefits across both HER2-low and HER2-ultralow groups, suggesting no need for further differentiation between these categories. While safety remained aligned with expectations, interstitial lung disease continues to pose a risk. The findings, presented at the ESMO Congress 2024, also confirmed trastuzumab deruxtecan’s role in preserving quality of life compared to chemotherapy. #health #healthresearch #healthsolutions #scientificcommunication #scientificresearch #researchanddevelopment #oncology

New!🦞 Circulating interleukin-8 and #osteopontin are promising biomarkers of clinical outcomes in advanced #melanoma patients treated with targeted therapy ------------------- Circulating cytokines can represent non-invasive biomarkers to improve prediction of clinical outcomes of cancer patients. In this study by Stefania D'Atri et al plasma levels of IL-8, CCL4, osteopontin, LIF and BDNF were determined at baseline (T0), after 2 months of therapy (T2) and, when feasible, at progression (TP), in 70 melanoma patients treated with BRAF and MEK inhibitors. The association of baseline cytokine levels with clinical response, progression-free survival (PFS) and overall survival (OS) was evaluated. Look here👇 https://lnkd.in/dE3cn4qW #CirculatingCytokines #Survival IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Evaluating Nivolumab+Ipilimumab vs. Nivolumab in Advanced Tumours with High Mutational Burden A phase 2 study (CheckMate 848) evaluated nivolumab (anti-PD1)+ipilimumab (anti-CTLA-4) versus nivolumab alone in patients with metastatic or unresectable solid tumours with high tumour mutational burden (TMB-H) determined by tissue (tTMB) or blood (bTMB). Among 201 patients, those with tTMB-H showed a higher objective response rate (ORR) with the combination therapy (38.6%) compared to nivolumab alone (29.8%). For bTMB-H patients, the ORR was 22.5% with combination therapy and 15.6% with monotherapy. The safety profile was manageable, suggesting potential benefit for TMB-H patients. The link to the original article is in the comments. If you found this post valuable, give it a like and share it with your network! 😃 #CancerResearch #Immunotherapy #ClinicalTrials #Oncology #PrecisionMedicine #Ipilimumab #Nivolumab #CheckPointInhibitors Be at the forefront of cancer immunotherapy breakthroughs! 🔬 Subscribe for FREE to my monthly Newsletter for a dose of knowledge and the latest advancements: https://lnkd.in/ec5sV-iP  📧 #ImmunotherapyFrontiers #StayInformed #ImmunotherapyExploration #DontMissOut"

https://lnkd.in/g_3hMi8N Article title: Survival benefits and safety of chemotherapy regimens for pancreatic cancer: An umbrella review of meta-analyses of randomized controlled trials Author(s): Aditi Kharat; Chia Jie Tan; Manit Saeteaw; Anindit Chhibber; Joseph Biskupiak; Sajesh K Veettil; Nathorn Chaiyakunapruk Journal: Annals of Pancreatic Disorders and Treatment Journal ISSN: 2692-4730 Abstract: Introduction: Several meta-analyses have reported the survival benefits and safety issues of chemotherapy regimens for pancreatic cancer (PC). The aim was to perform an umbrella review to summarize the existing evidence from meta-analyses of randomized controlled trials (RCTs). Methods: EMBASE, PubMed, Cochrane database of systematic reviews, and Epistemonikos were searched from inception to October 31st, 2021.Methodological quality was assessed using the A Measurement Tool to Assess Systematic Reviews (AMSTAR-2). The quality of evidence was evaluated using GRADE criteria (Grading of Recommendations, Assessment, Development, and Evaluations). #PancreaticCancer #ChemotherapyRegimens #FOLFIRINOX #GemcitabineNabPaclitaxel #UmbrellaReview #Resected #AdvancedPancreaticCancer #AcutePancreatitis #AcutePancreatitisSymptoms #BiliaryDyskinesia #ChronicPancreatitis #GallBladderSymptoms #GallbladderDisease #GallstonePancreatitis #HereditaryPancreatitis #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #InflamedPancreas #PancreasAnatomy #PancreasPain #Pancreatectomy #PancreaticDisorder #PancreaticDuct #PancreaticEnzymeReplacementTherapy #Pancreatitis #PancreatitisSymptoms #ProtonTherapyPancreaticCancer #SwollenPancreas

📢 AstraZeneca's NIAGARA Phase III trial has shown that IMFINZI (durvalumab) combined with chemotherapy significantly enhances treatment outcomes for muscle-invasive bladder cancer (MIBC) patients worldwide. The trial reported a 32% reduction in disease progression and recurrence risk, alongside a 25% decrease in mortality compared to neoadjuvant chemotherapy alone. These findings were showcased at a Presidential Symposium during the 2024 ESMO - European Society for Medical Oncology Congress in Barcelona, Spain and were concurrently published in The New England Journal of Medicine. Tom Powles Susan Galbraith For further details, please refer to the full article: https://lnkd.in/eZ3v9v76 #OncoDaily #Oncology #Cancer #Health #Medicine #ESMO24 #CancerTreatment #BladderCancer #Chemotherapy

The FDA has just approved the combination of pembrolizumab (KEYTRUDA®) with chemotherapy as a first-line treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma. This approval is based on the pivotal Phase 2/3 IND.227/KEYNOTE-483 trial, which demonstrated a significant improvement in overall survival compared to chemotherapy alone This is a monumental step forward in the fight against this aggressive cancer, offering new hope to patients who previously had limited treatment options. The combination therapy not only extends survival but also improves progression-free survival and objective response rates². As a medical professional dedicated to advancing cancer treatment, I am excited about the potential impact this approval will have on patient outcomes. Kudos to the researchers, clinicians, and patients who made this breakthrough possible! #Oncology #CancerResearch #FDAApproval #Pembrolizumab #Chemotherapy #Mesothelioma #MedicalInnovation

New!⛳️ TRF2 as novel marker of tumor response to #taxane-based therapy: from mechanistic insight to clinical implication ------------------------------- Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) – the most aggressive BC form – is refractory to endocrine and most of the target therapies. In this view, taxane-based therapy still represents the elective strategy for the treatment of this tumor. Telomeric Binding Factor 2 (TRF2), a key regulator of telomere integrity that is over-expressed in several tumors, including TNBC, has been recently found to plays a role in regulating autophagy, a degradative process that is involved in drug detoxification. Based on these considerations, Pasquale Zizza, Annamaria Biroccio et al. pointed, here, at investigating if TRF2, regulating autophagy, can affect tumor sensitivity to therapy. Look here👇 https://lnkd.in/drPMymCK #BreastCancer #TelomericBindingFactor #Autophagy #DrugSensitivity IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

  Recent Publication: Findings from the GAIN2 Study Excited to share the latest results from our #GAIN2 trial (#GBG 68), comparing two dose-dense #chemotherapy regimens in early breast cancer. 📊 The study evaluated pathological complete response (#pCR) and overall survival (#OS) in patients receiving either: 👉 Intense dose-dense #epirubicin, #nab-#paclitaxel, and #cyclophosphamide (iddEnPC), or a tailored, leukocyte nadir-based regimen of dose-dense EC and #docetaxel (dtEC-dtD). 🗝 Key findings: ✔ After a median follow-up of 6.5 years, both regimens showed similar 5-year OS rates (iddEnPC 90.8%, dtEC-dtD 90.0%). ✔ In the neoadjuvant cohort, iddEnPC led to a significantly higher pCR rate (51.2% vs. 42.6%). ✔ Notably, #TNBC #patients receiving iddEnPC achieved an impressive 45% pCR rate. ❕ Patients who achieved pCR had markedly better iDFS and OS, though overall survival was similar regardless of pCR status. ❕ For full details, check out the publication: https://lnkd.in/eSeZ9FW8   #BreastCancerAwarenessMonth #BreastCancer #Survival #Oncology #ClinicalTrials